product name Kartogenin
Description: Kartogenin is an activator of the smad4/smad5 pathway, it induces the selective differentiation of multipotent mesenchymal stem cells (MSCs) into chondrocytes. Kartogenin binds to filamin A, and disrupts the specific interaction between filamin A and CBFβ (core-binding factor β subunit). Apparently, kartogenin induces chondrogenesis by regulating the nuclear localization of CBFβ.
References: Biochem Biophys Res Commun. 2014 Jul 18;450(1):568-74; Science. 2012 May 11;336(6082):717-21.
317.34
Formula
C20H15NO3
CAS No.
4727-31-5
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 63 mg/mL (198.5 mM)
Water: <1 mg/mL
Ethanol: 18 mg/mL (56.7 mM)
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: Kartogenin induces chondrocyte differentiation from hMSCs by enhancing the nuclear localization of CBFβ, and protects articular chondrocytes. Kartogenin promotes the type-I collagen synthesis of dermal fibroblasts via activation of the smad4/smad5 pathway without obvious cytotoxicity on fibroblasts’ viability, morphology and survival. Kinase Assay: Cell Assay: For the cell viability assay, fibroblasts are seeded on six-well plates, followed by Kartogenin or DMSO treatment. According to the manufacturer’s instructions, cell viability and viability are assessed by AlamarBlue assay. |
|---|---|
| In Vivo | Kartogenin promotes cartilage repair in collagenase VII (10 μM)– and surgery (100 μM)-induced OA models in mice. Kartogenin (100 nM) also stimulats collagen synthesis in the mouse dermis. In addition, Kartogenin stimulates mouse limb skeletal growth and synovial joint development. |
| Animal model | Collagenase VII-induced OA mouse model and Surgery-induced OA mouse model |
| Formulation & Dosage | Dissolved in saline; 10 μM or 100 μM; Intra-articular injection |
| References | Biochem Biophys Res Commun. 2014 Jul 18;450(1):568-74; Science. 2012 May 11;336(6082):717-21. |
